Almac Open CLIA lab for Biomarker Clinical Trials

By Almac Group, PRNE
Tuesday, March 29, 2011

CRAIGAVON, Northern Ireland, March 30, 2011 - Almac's Diagnostics business unit today announced the opening of its CLIA
registered laboratory.

The opening of the Almac CLIA Laboratory supports the company's ongoing
Biomarker Discovery and Development Strategy by enabling the use of novel
tests to stratify and enrich prospective clinical trails. This ability is of
key importance as Almac begins to transition the novel biomarkers that they
have developed into clinical use, with the resulting potential to inform the
drug development process and target therapies to responsive patients.

In addition to standard molecular tests, Almac have a pipeline of both
internal clinical tests and companion diagnostic tests with Pharma partners
in development that will be delivered from the Almac CLIA Laboratory.

Professor Paul Harkin, President and Managing Director of Almac's
Diagnostics business, said:

"We are very happy to announce the launch of our CLIA lab, which has been
opened to meet both our needs and the needs for our Pharma partners. We have
come to a point where the biomarkers we have discovered and assays that we
have developed are being used to stratify patients, enrich clinical trials
and impact patient treatment decisions. As such, CLIA is a key necessity for
the processing of these samples."

Almac's genomics laboratories have been supporting biomarker discovery
projects for eight years and already operate under ISO17025 accreditation and
work to the principles of GLP.

Notes to Editors

About Almac

Almac's Diagnostics business unit is focused on the discovery and
development of biomarkers. It utilises its proprietary technology, extensive
experience and expertise to offer solutions to biotech and Pharma partners.
Almac focus on providing a range of services including exploratory biomarker
discovery studies, verification studies for existing markers, assay
development and biomarker validation.

The Almac Group offers a broad range of services from R&D, biomarker
discovery and development, API manufacture, formulation development, clinical
trial supply and IXRS technology (IVRS/IWRS), to commercial-scale
manufacture. Almac provides services to more than 600 companies, including
all the world leaders in the pharmaceutical and biotech sectors.

The company employs almost 3,000 individuals and is headquartered in
Craigavon, Northern Ireland. US operations are based in Pennsylvania, North
and California. Staff have now transferred to Almac's new $120m
North American Headquarters which is now fully operational.

For more information about the Almac Group, please visit or e-mail

Tristan Jervis - +44(0)207-861-3019

Tristan Jervis - +44(0)207-861-3019, e-mail: info at

Pharmaceuticals News

Almac Group News

will not be displayed